Clinical Trial Update: "Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating re-stimulated tumor-infiltrating lymphocytes (TILs) with interleukin-2 for platinum-resistant recurrent cancers of the ovary, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Interleukin-2 (interleukin-2)
• Tumor-infiltrating lymphocytes (TILs) therapy (tumor-infiltrating lymphocytes)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Recurrent, Platinum-resistant | Phase 1 | Status: ACTIVE_NOT_RECRUITING